Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443535 | 0.82 | OPRM1 (0.74) | OPRM1OPRL1ITGB3ITGA2BCYP3A4 | |
| SCHEMBL17438597 | 0.81 | OPRM1 (0.69) | OPRM1OPRL1MAPTITGB3ITGA2B | |
| SCHEMBL17438809 | 0.74 | OPRM1 (0.53) | OPRM1OPRL1MAPTITGB3ITGA2B | |
| SCHEMBL17438976 | 0.73 | OPRM1 (1.00) | OPRM1OPRL1HSD11B1 | |
| SCHEMBL17439114 | 0.72 | OPRM1 (0.54) | OPRM1OPRL1ITGB3ITGA2BHSD11B1 | |
| SCHEMBL17439089 | 0.71 | OPRM1 (0.53) | OPRM1OPRL1MAPTITGB3ITGA2B | |
| SCHEMBL17439010 | 0.70 | OPRM1 (0.66) | OPRM1OPRL1MAPTITGB3ITGA2B | |
| SCHEMBL17438890 | 0.69 | OPRM1 (0.54) | OPRM1OPRL1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17438883 | 0.69 | OPRM1 (0.56) | OPRM1OPRL1ITGB3ITGA2B | |
| SCHEMBL17438745 | 0.69 | OPRM1 (0.64) | OPRM1OPRL1MAPTITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | claimed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | claimed |
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | GRUENENTHAL GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202345-B2 | Substituted azaspiro(4.5)decane derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885MAPT 3806/4885 |
| US-20160016903-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885MAPT 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.